ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
Fierce Pharma
SEPTEMBER 14, 2024
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). | In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer. Now, the PD-1 inhibitor has gold-standard overall survival data to back its case.
Let's personalize your content